Aspargo Laboratories Inc., a privately held, clinical stage pharmaceutical company, has announced the results of its pre-Investigational New Drug (pre-IND) meeting with the FDA, where the FDA addressed Aspargo’s questions and provided guidance on the company’s Sildenafil Oral Spray for the treatment of erectile dysfunction (ED).   The FDA was supportive of a single dose bioequivalent study comparing Aspargo’s Sildenafil Oral Spray, an oral liquid suspension formulation of sildenafil citrate, wit...